Click for new scientific resources and news about Corona[COVID-19]

Paper Information

Journal:   IRANIAN JOURNAL OF CLINICAL INFECTIOUS DISEASES   2006 , Volume 1 , Number 3; Page(s) 121 To 125.
 
Paper: 

IN–VITRO SUSCEPTIBILITY OF MYCOBACTERIUM TUBERCULOSIS TO AMOXICILLIN–CLAVULANATE

 
 
Author(s):  VARSHOUCHI M.*, RASTGAR MOHAMMAD HOSSEIN, RAFI A.A.N., NAGILI B.
 
* INFECTIOUS DISEASES AND TROPICAL MEDICINE RESEARCH CENTER, TABRIZ UNIVERSITY OF MEDICAL SCIENCES, TABRIZ, IRAN
 
Abstract: 

Background: The evidence of rapid spread of multidrug resistant Mycobacterium tuberculosis (MDR–TB) strains especially in high risk communities; persuade clinicians to find new drugs for this problem. b– lactams with few or no side effects has been reviewed as an alternative drugs for this issue. This study carried out to determine the effectiveness of amoxicillin–clavulanate in a group of Iranian patients.
Materials and methods: Amoxicillin–clavulanate was studied in five different minimal inhibitory concentrations (32- 512
mg/ml) on 90 clinical strains of Mycobacterium tuberculosis (50 strains were sensitive and 40 were resistant to firstline anti-TB drugs).
Results: All strains were found resistant to amoxicillin–clavulanate in concentration of 32
mg/ml. Only in concentration of 64 mg/ml, sensitive strains (to first-line anti-TB drugs) were significantly more susceptible to amoxicillin–clavulanate than resistant strains. Five different MICs showed a non-significant difference in susceptibility to amoxicillin– clavulanate between strains with various resistance patterns to first-line anti-TB drugs. However, in 29 strains MIC were above 512mg/ml.
Conclusion: Although amoxicillin–clavulante might be a suitable candidate as a second-line anti-TB drug, further clinical trials are required to draw a firm conclusion.

 
Keyword(s): MYCOBACTERIUM TUBERCULOSIS, MULTIDRUG RESISTANT, AMOXICILLIN-CLAVULANATE
 
References: 
  • ندارد
 
  pdf-File tarjomyar Yearly Visit 64
 
Latest on Blog
Enter SID Blog